
Gain Therapeutics, Inc.: shareholders and insiders
Price
$1.00
November 20, 2026Market cap $44M
What Ploutos Investor adds for Gain Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors, from their own Form 4 filings.
Sorry, we do not have enough data
for purchases and sales by Gain Therapeutics's insiders
Why?
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
No filing over 5%
Since Dec 18, 2024 nobody has filed a Schedule 13D or 13G for Gain Therapeutics shares.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Greenlight / DME (Einhorn)In the quarter
- Citadel Advisors (Griffin)In the quarter+10%
- Renaissance TechnologiesIn the quarter
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Greenlight / DME (Einhorn) | 566.1K | $1.0M | 0.03% | |
| Citadel Advisors (Griffin) | 170.2K | +10% | $300.0K | 0.00% |
| Renaissance Technologies | 182.6K | $300.0K | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 7.17% of its shares outstanding were held short, +4.4% since the report before.
- Shares held short
- 3.19M
- 7.17%
- Since the report before3.06M on Sep 30, 2026
- +4.4%
- 6.5
- 490.2K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 74%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 182.4K
- Nov 15, 2023: Shares held short 176.5K
- Nov 30, 2023: Shares held short 143.2K
- Dec 15, 2023: Shares held short 107.4K
- Dec 29, 2023: Shares held short 62.3K
- Jan 12, 2024: Shares held short 103.5K
- Jan 31, 2024: Shares held short 121.3K
- Feb 15, 2024: Shares held short 137.6K
- Feb 29, 2024: Shares held short 134.6K
- Mar 15, 2024: Shares held short 156.7K
- Mar 28, 2024: Shares held short 138.1K
- Apr 15, 2024: Shares held short 149.6K
- Apr 30, 2024: Shares held short 154.2K
- May 15, 2024: Shares held short 100.7K
- May 31, 2024: Shares held short 80.5K
- Jun 14, 2024: Shares held short 500.3K
- Jun 28, 2024: Shares held short 193.0K
- Jul 15, 2024: Shares held short 83.8K
- Jul 31, 2024: Shares held short 184.6K
- Aug 15, 2024: Shares held short 188.2K
- Aug 30, 2024: Shares held short 555.4K
- Sep 13, 2024: Shares held short 580.3K
- Sep 30, 2024: Shares held short 654.3K
- Oct 15, 2024: Shares held short 572.0K
- Oct 31, 2024: Shares held short 658.3K
- Nov 15, 2024: Shares held short 718.7K
- Nov 29, 2024: Shares held short 580.6K
- Dec 13, 2024: Shares held short 334.7K
- Dec 31, 2024: Shares held short 335.2K
- Jan 15, 2025: Shares held short 374.6K
- Jan 31, 2025: Shares held short 365.1K
- Feb 14, 2025: Shares held short 462.2K
- Feb 28, 2025: Shares held short 348.8K
- Mar 14, 2025: Shares held short 326.7K
- Mar 31, 2025: Shares held short 302.7K
- Apr 15, 2025: Shares held short 279.7K
- Apr 30, 2025: Shares held short 295.8K
- May 15, 2025: Shares held short 290.2K
- May 30, 2025: Shares held short 291.8K
- Jun 13, 2025: Shares held short 232.3K
- Jun 30, 2025: Shares held short 252.1K
- Jul 15, 2025: Shares held short 198.8K
- Jul 31, 2025: Shares held short 243.0K
- Aug 15, 2025: Shares held short 210.9K
- Aug 29, 2025: Shares held short 233.3K
- Sep 15, 2025: Shares held short 377.1K
- Sep 30, 2025: Shares held short 422.3K
- Oct 15, 2025: Shares held short 1.27M
- Oct 31, 2025: Shares held short 910.7K
- Nov 14, 2025: Shares held short 1.78M
- Nov 28, 2025: Shares held short 1.26M
- Dec 15, 2025: Shares held short 2.07M
- Dec 31, 2025: Shares held short 2.67M
- Jan 15, 2026: Shares held short 2.48M
- Jan 30, 2026: Shares held short 2.98M
- Feb 13, 2026: Shares held short 3.04M
- Feb 27, 2026: Shares held short 2.88M
- Mar 13, 2026: Shares held short 2.87M
- Mar 31, 2026: Shares held short 3.28M
- Apr 15, 2026: Shares held short 3.33M
- Apr 30, 2026: Shares held short 3.44M
- May 15, 2026: Shares held short 3.16M
- May 29, 2026: Shares held short 3.20M
- Jun 15, 2026: Shares held short 3.87M
- Jun 30, 2026: Shares held short 3.61M
- Jul 15, 2026: Shares held short 3.59M
- Jul 31, 2026: Shares held short 3.21M
- Aug 14, 2026: Shares held short 2.95M
- Aug 31, 2026: Shares held short 2.80M
- Sep 15, 2026: Shares held short 2.89M
- Sep 30, 2026: Shares held short 3.06M
- Oct 15, 2026: Shares held short 3.19M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading52.6% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 52.6% of the shares in the reported trades were short sales, against 53.4% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 52.6%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 53.4%
- Change
- -0.8 pts
- Short sales a dayon average, of 482.0K shares
- 253.4K
- More than atof 3,666 US-listed companies, same days
- 58%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 48.1%
- Oct 15, 2026: Short sales 51.3%
- Oct 16, 2026: Short sales 58.9%
- Oct 19, 2026: Short sales 50.8%
- Oct 20, 2026: Short sales 34.2%
- Oct 21, 2026: Short sales 39.4%
- Oct 22, 2026: Short sales 63.4%
- Oct 23, 2026: Short sales 52.8%
- Oct 26, 2026: Short sales 54%
- Oct 27, 2026: Short sales 33%
- Oct 28, 2026: Short sales 48.1%
- Oct 29, 2026: Short sales 57.7%
- Oct 30, 2026: Short sales 59.7%
- Nov 2, 2026: Short sales 57.7%
- Nov 3, 2026: Short sales 66%
- Nov 4, 2026: Short sales 48.2%
- Nov 5, 2026: Short sales 47.3%
- Nov 6, 2026: Short sales 51%
- Nov 9, 2026: Short sales 45.1%
- Nov 10, 2026: Short sales 51.6%
- Nov 11, 2026: Short sales 41%
- Nov 12, 2026: Short sales 59.6%
- Nov 13, 2026: Short sales 48.6%
- Nov 16, 2026: Short sales 37.4%
- Nov 17, 2026: Short sales 60.2%
- Nov 18, 2026: Short sales 48.1%
- Nov 19, 2026: Short sales 34.5%
- Nov 20, 2026: Short sales 42.8%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Eric I RichmanDirectorDirectly289.6K
- Khalid IslamExecutive ChairmanDirectly50.0K
- Jeffrey Scott RileyDirectorDirectly30.0K
- Gene MackCFO and Interim CEODirectly14.4K
- Matthias AlderChief Executive OfficerDirectly5,286
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Eric I RichmanDirector | 289.6K | – | Jul 1, 2024 | Form 4 |
| Khalid IslamExecutive Chairman | 50.0K | – | Aug 9, 2024 | Form 4 |
| Jeffrey Scott RileyDirector | 30.0K | – | Mar 28, 2024 | Form 4 |
| Gene MackCFO and Interim CEO | 14.4K | – | Aug 9, 2024 | Form 4 |
| Matthias AlderChief Executive Officer | 5,286 | – | Dec 21, 2023 | Form 4 |
A lower bound: it counts only the 5 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
2 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 38
- Q4 2025: Managers 48
- Q1 2026: Managers 42
- Q2 2026: Managers 50
Institutional investors by quarter
The fund managers holding GANX, quarter by quarter, from Q1 2021 to Q2 2025, 18 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 50 managers held 9.23M shares, worth $19M. During the quarter 12 opened a position, 4 closed one, 14 added and 9 trimmed.
The largest holders, Q2 2026
- Marshall WaceIn the quarter+8.7%
- Cambridge Investment Research AdvisorsIn the quarter+100%
- Potomac Capital ManagementIn the quarter-6.2%
- Gsa Capital PartnersIn the quarter+102%
- Jones Financial Companies LllpIn the quarter-3.6%
- Greenlight / DME (Einhorn)In the quarter
- Vanguard Capital ManagementIn the quarter+20%
- Geode Capital ManagementIn the quarter+1.4%
- BlackRockIn the quarter+22%
- Vanguard Fiduciary TrustIn the quarter+0.7%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Marshall Wace | 1.92M | +8.7% | $3.9M |
| Cambridge Investment Research Advisors | 1.14M | +100% | $2.3M |
| Potomac Capital Management | 946.4K | -6.2% | $1.9M |
| Gsa Capital Partners | 632.1K | +102% | $1.3M |
| Jones Financial Companies Lllp | 608.6K | -3.6% | $1.1M |
| Greenlight / DME (Einhorn) | 566.1K | $1.1M | |
| Vanguard Capital Management | 480.3K | +20% | $974.9K |
| Geode Capital Management | 453.5K | +1.4% | $921.4K |
| BlackRock | 275.0K | +22% | $558.2K |
| Vanguard Fiduciary Trust | 231.5K | +0.7% | $470.0K |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Gain Therapeutics's filings show?
Who buys and sells is one part of Gain Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have GANX's insiders bought or sold?
From Jul 17, 2026 to Oct 30, 2026 Gain Therapeutics's insiders reported no purchase or sale of shares on the market.
Which well-known managers hold GANX?
3 of the managers we track held the shares on Sep 30, 2026. The largest position was Greenlight / DME (Einhorn)'s, worth $1.0M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.